Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | APAF1 | O14727 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | MPO | P05164 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2945687 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2KDM4EMAPTKMT2AL3MBTL1 | |
| SCHEMBL18862333 | 0.87 | KDM4E (0.59) | SMN1; SMN2KDM4EMAPTKMT2AL3MBTL1 | |
| SCHEMBL2491934 | 0.87 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4EMAPTKMT2AL3MBTL1 | |
| SCHEMBL10701840 | 0.87 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4EMAPTKMT2AL3MBTL1 | |
| SCHEMBL10701837 | 0.87 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4EMAPTKMT2AL3MBTL1 | |
| SCHEMBL4309022 | 0.87 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4EMAPTKMT2AL3MBTL1 | |
| SCHEMBL4309019 | 0.87 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4EMAPTKMT2AL3MBTL1 | |
| SCHEMBL31036050 | 0.85 | SMN1; SMN2 (0.62) | SMN1; SMN2KDM4EMAPTKMT2AL3MBTL1 | |
| SCHEMBL30661929 | 0.85 | SMN1; SMN2 (0.62) | SMN1; SMN2KDM4EMAPTKMT2AL3MBTL1 | |
| SCHEMBL27577681 | 0.85 | SMN1; SMN2 (0.62) | SMN1; SMN2KDM4EMAPTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112538040-A | Preparation method of tryptophan oxide | 艾希尔（深圳）药物研发有限公司 | 2021-03-23 | — | — | CN | claimed |
| US-20100297680-A1 | METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE | UNIVERSITY OF WASHINGTON (US) | 2010-11-25 | — | — | US | claimed |
| US-20080261250-A1 | Methods for Assessing the Risk for Development of Cardiovascular Disease | UNIVERSITY OF WASHINGTON (US) | 2008-10-23 | — | — | US | claimed |
| EP-1787116-A4 | METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE | UNIV WASHINGTON (US) | 2008-05-28 | — | — | EP | claimed |
| EP-1787116-A1 | METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE | University of Washington (US) | 2007-05-23 | — | — | EP | claimed |
| WO-2006014628-A1 | METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE | UNIVERSITY OF WASHINGTON (US) | 2006-02-09 | — | — | WO | claimed |
| US-20250289868-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | REGENERON PHARMA (US) | 2025-09-18 | — | — | US | disclosed |
| US-12338274-B2 | Anti-VEGF protein compositions and methods for producing the same | REGENERON PHARMACEUTICALS, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250197474-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | REGENERON PHARMACEUTICALS, INC. | 2025-06-19 | — | — | US | disclosed |
| US-12319728-B2 | Anti-VEGF protein compositions and methods for producing the same | REGENERON PHARMACEUTICALS, INC. (US) | 2025-06-03 | — | — | US | disclosed |
| EP-4524147-A2 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | Regeneron Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4524148-A2 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | Regeneron Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4524236-A2 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | Regeneron Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-7749729-B2 | Methods for assessing the risk for development of cardiovascular disease | UNIVERSITY OF WASHINGTON (US) | 2010-07-06 | — | — | US | disclosed |
| US-20080261250-A1 | Methods for Assessing the Risk for Development of Cardiovascular Disease | UNIVERSITY OF WASHINGTON (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1787116-A4 | METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE | UNIV WASHINGTON (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1865950-A1 | COMPOUNDS USEFUL AS MODULATORS OF THE PROTEASOME ACTIVITY | The Centre National de la Recherche Scientifique (FR) | 2007-12-19 | — | — | EP | disclosed |
| EP-1787116-A1 | METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE | University of Washington (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006105811-A1 | COMPOUNDS USEFUL AS MODULATORS OF THE PROTEASOME ACTIVITY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006014628-A1 | METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE | UNIVERSITY OF WASHINGTON (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338274-B2 | Anti-VEGF protein compositions and methods for producing the same | VEGFA, HDGF, PDGFA | SMN1; SMN2 3864/4885KDM4E 3284/4885MAPT 2868/4885 |
| US-20250197474-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | VEGFA, HDGF, PDGFA | SMN1; SMN2 3864/4885KDM4E 3284/4885MAPT 2868/4885 |
| US-12319728-B2 | Anti-VEGF protein compositions and methods for producing the same | VEGFA, HDGF, PDGFA | SMN1; SMN2 3864/4885KDM4E 3284/4885MAPT 2868/4885 |
| US-20250289868-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | VEGFA, HDGF, PDGFA | SMN1; SMN2 3864/4885KDM4E 3284/4885MAPT 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.